ADDF and FMM Partner to Support Novel Research for Mitochondrial-Directed Therapies


Research could lead to development of new therapies to treat a variety of mitochondrial diseases, including Autism, Alzheimer’s, Parkinson’s and Lou Gehrig’s disease

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Foundation for Mitochondrial Medicine (FMM) announced today that they have awarded $200,000 in funding to James Bennett, M.D., Ph.D. to further research gene therapy of mitochondrial protein in the brains of mice with experimental Alzheimer’s disease. Bennett is studying rhTFAM, a novel human mitochondrial protein shown to increase mitochondrial function in cell and animal models. The protein has shown to restore memory function of aged mice while increasing mitochondrial function in brains, suggesting it has great potential to do the same in humans with impaired cognition and early Alzheimer’s disease.

ADDF and W. Garfield Weston Foundation Collaborate to Fund Clinical Trial in Alzheimer’s


The Alzheimer’s Drug Discovery Foundation of Canada (ADDF-Canada) and The W. Garfield Weston Foundation today announced a new funding collaboration to support a clinical trial investigating the potential for hypertension drugs to slow Alzheimer’s disease progression. The trial will be led by Dr. Sandra Black and the Toronto Dementia Research Alliance at the University of Toronto.

Foundations Partner on $3M Initiative to Accelerate Research + Discover Treatments for Alzheimer’s


Research to Focus on Repurposing Drugs for Alzheimer’s Disease and Related Dementias

Today the Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society (UK) announced a new partnership that will provide funding for research in Alzheimer’s disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.

ADDF Expands its ADDF ACCESS Program to Improve Quality and Efficiency of Drug Research


The Alzheimer’s Drug Discovery Foundation (ADDF) announced yesterday the launch of its newly expanded ADDF ACCESS program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases. Through the effective selection of CROs and use of their services, researchers may be able to accelerate their research and bring novel therapies to patients faster.

The ING New York City Marathon: Who Runs? Chris Johnson.


Why Run? To raise awareness and money for the Alzheimer’s Drug Discovery Foundation.

What for? To honor his father, New York Giants Running Back, Ron Johnson, diagnosed in 2008 with early-onset Alzheimer’s disease…

New York N.Y. October 24th,  2013. This is one story of a runner with a reason. Thirty-one year old Chris Johnson, son of legendary New York Giants Running Back, Ron Johnson has taken up the cause to find the prevention, treatment and ultimately cure for a disease that once upon a time was as mysterious and taboo as cancer used to be. Why?

ADDF Partners with Harrington Discovery Institute at University Hospitals Case Medical Center


Partnership increases critical support for researchers’ efforts to find new therapies to treat Alzheimer’s disease

October 24, Cleveland, Ohio - The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals (UH) Case Medical Center announced today a newly formed partnership that will leverage their combined expertise and resources to advance highly promising Alzheimer’s disease drug discovery projects conducted in academic medical institutions nationwide.

ADDF Presents its September 2013 14th International Conference on Alzheimer’s Drug Discovery


The Alzheimer’s Drug Discovery Foundation (ADDF) presents its annual fall conference, the 14th International Conference on Alzheimer’s Drug Discovery taking place on September 9-10, 2013 at the Hyatt Regency in Jersey City, NJ, across the Hudson River from New York City.

Read Release

The Hill Op-Ed: Dr. Fillit + Other Leaders in Alzheimer’s Community Comment on Amyvid Reimbursement


Earlier this month, the Centers for Medicare and Medicaid Services (CMS) issued a draft Decision Memorandum to deny Medicare reimbursements to patients using an innovative FDA-approved Alzheimer's diagnostic technology designed to help physicians identify whether patients with signs of cognitive impairment may have Alzheimer's or are in fact suffering from another form of dementia. This information is vital to patients, their providers, choices regarding their treatment and their ultimate health outcomes.

Go to top